Company Overview
Company Type: Public Company
Website: www.xortx.com
Number of Employees: 3
Ticker: XRTX (TSXV)
Year Founded: -


Business Description
XORTX Therapeutics Inc., a late stage clinical pharmaceutical company, engages in the development and commercialization of therapies to treat progressive kidney diseases, diabetes, insulin resistance, metabolic syndrome, diabetes, diabetic nephropathy, and infection. It develops XRx-008, a late clinical stage program therapy for autosomal dominant polycystic kidney disease; XRx-101, an uric acid lowering agent used to treat patients infected with the coronavirus COVID-19 infection and acute kidney injury (AKI) associated health consequences; and XRX-225, a program for treatment of type 2 diabetic nephropathy. The company has a collaboration and license agreements with the Icahn School of Medicine to study the incidence of AKI and hyperuricemia in patients hospitalized with COVID-19; and with the University of Florida Research Foundation, Inc. XORTX Therapeutics Inc. is based in Alberta Beach, Canada.

Financial Information (Currency: CAD, in mm) 
Market Capitalization
9.7
EBITDA
(10.1)
Total Enterprise Value
1.6
TEV/EBITDA
NM
EBIT
(10.2)
Cash & ST Invst.
8.5
P/Diluted EPS Before Extra
NM
Net Income
(9.3)
Total Debt
0.1
Price/Tang BV
1.0x
Capital Expenditure
0.0
Total Assets
10.7
Total Debt/EBITDA
NM




Currency in CAD in mm, LTM as of Jun-30-2023 TEV and Market Cap are calculated using a close price as of Oct-04-2023


Estimates Snapshot (Current Fiscal Year End: Dec-31-2023 | Currency: CAD)
Periodic Estimates
Current FQ
Current FQ+1
Current FY
Current FY+1
NTM
EPS Normalized
(0.26)
(0.26)
(1.35)
(1.10)
(1.06)

Forward Multiples (Current FY)

Price/Earnings
NM

Non-Periodic Estimates

Recommendation
Buy (1.00)


Key Professionals
Name
Title
Davidoff, Allen Warren
Founder, CEO, President & Director
Fairbairn, James Neville
Interim Chief Financial Officer
Rigopoulos, Nick 
Director of Communications
Sans, David 
Director of Corporate Development
Evans, Stacy 
Chief Business Officer
Haworth, Stephen 
Chief Medical Officer
MacDonald, David 
Consultant of Clinical Operations
May, Charlotte 
Corporate Secretary

Key Board Members
Name
Title
Giovinazzo, Anthony J.
Independent Chair of the Board
Davidoff, Allen Warren
Founder, CEO, President & Director
Klassen, Ian Mcculloch
Independent Director
Van Damme, Paul Joseph
Independent Director
Bjornstad, Petter 
Member of Clinical Advisory Board
Edelstein, Charles 
Member of the Advisory Board
Farley, William J.
Independent Director
Johnson, Richard J.
Member of Clinical Advisory Board
Maese, Federico 
Member of Clinical Advisory Board
Pratt, Raymond Dennis
Independent Director
Rastogi, Anjay 
Member of the Clinical Advisory Board
ter Keurs, Henk E. D. J.
Member of Scientific Advisory Board


Primary Industry Classification
Pharmaceuticals


Primary Office Location
3710 – 33rd Street NW | Alberta Beach, AB | T2L 2M1 | Canada
Phone: 403 455 7727   

Current and Pending Investors
Cato BioVentures

Stock Quote and Chart (Currency: CAD)
Last  (Delayed)
 0.46
Market Cap (mm)
8.3
Open
 0.54
Shares Out. (mm)
18.0
Previous Close
 0.46
Float %
91.2%
Change on Day
(0.08)
Shares Sold Short (mm)
-
Change % on Day
(14.8)%
Dividend Yield %
-
Day High/Low
 0.54/ 0.40
Diluted EPS Excl. Extra Items
(0.59)
52 wk High/Low
 1.65/ 0.40
P/Diluted EPS Before Extra
NM
Volume (mm)
0.16
Avg 3M Dly Vlm (mm)
0.01
Beta 5Y
0.19


 
Delayed Quote** | Last Updated on Oct-05-2023 12:00 AM (GMT-5)
TSXV:XRTX - Common Stock


Company Notes
No Company Notes exist.


Strategy Notes
No Strategy Notes exist.


Current and Pending Subsidiaries / Investments
Company Name
Business Description
Geography
Primary Industry
LTM Total Rev.($mm)
LFQ Total Assets ($mm)
LFQ Total Debt ($mm)
APAC Resources Inc.
As of January 9, 2018, APAC Resources Inc. was acquired by XORTX Therapeutics Inc., in a reverse merger transaction. APAC Resources Inc. engages in the acquisition and exploration of mineral properties in Canada. The company has an option agreement to acquire 100% interest in the Shuswap Silver project located in the area of Sicamous, British Columbia. APAC Resources Inc. was incorporated in 2011 and is based in Vancouver, Canada.

United States and Canada
Diversified Metals and Mining
-
0.00
0.00


Last 5 Transactions
Announced Date
Closed Date
Transaction Type
Role
Target
Buyer/Investors
Sellers
Size($mm)
Feb-17-2023
-
Shelf Registration
Target
XORTX Therapeutics Inc. (TSXV:XRTX)


37.03
Jan-27-2023
-
Shelf Registration
Target
XORTX Therapeutics Inc. (TSXV:XRTX)


50.00
Sep-8-2022
Oct-4-2022
Public Offering
Target
XORTX Therapeutics Inc. (TSXV:XRTX)


5.00
Aug-11-2021
Oct-12-2021
Public Offering
Target
XORTX Therapeutics Inc. (TSXV:XRTX)


12.00
Jan-07-2021
Feb-10-2021
Private Placement
Target
XORTX Therapeutics Inc. (TSXV:XRTX)


4.83
* denotes that the relationship is proprietary


Last 5 Key Developments
Date
Event Type
Headline
Oct-05-2023
Delistings
XORTX Therapeutics Provides Nasdaq Compliance Update
Oct-04-2023
Company Conference Presentations
XORTX Therapeutics Inc. Presents at LD Micro Main Event XVI Conference 2023, Oct-04-2023 01:00 PM
Sep-13-2023
Company Conference Presentations
XORTX Therapeutics Inc. Presents at Autumn Equinox 2023 Webinar, Sep-13-2023 10:00 AM
Sep-11-2023
Company Conference Presentations
XORTX Therapeutics Inc. Presents at H.C. Wainwright 25th Annual Global Investment Conference, Sep-11-2023
Aug-04-2023
Executive Changes - CFO
XORTX Therapeutics Inc. Announces Chief Financial Officer Changes

M&A Advisors
McCarthy Tétrault LLP


Advisors
Most Recent Auditor
Smythe LLP
M&A Advisors
McCarthy Tétrault LLP
Public Offering Advisors
Dorsey & Whitney LLP, Fasken Martineau DuMoulin LLP, McCarthy Tétrault LLP, Smythe LLP, Troutman Pepper Hamilton Sanders LLP


Most Recent Auditor
Smythe Ratcliffe


Last 10 Investment Research Documents
Contributor
Analyst
Date/Time
Company
Headline
Type
Pages
S&P Global Compustat

04:11 AM
XRTX
XORTX Therapeutics Inc 2023_10_05
Reports
14
S&P Global Compustat

Sep 07, 2023 04:11 AM
XRTX
XORTX Therapeutics Inc 2023_09_07
Reports
14
GlobalData

Aug 18, 2023 04:47 AM
XRTX
XORTX Therapeutics Inc (XRTX.CVE) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
Reports
29
S&P Global Compustat

Jul 06, 2023 03:33 AM
XRTX
XORTX Therapeutics Inc 2023_07_06
Reports
14
S&P Global Compustat

Jun 01, 2023 04:31 AM
XRTX
XORTX Therapeutics Inc 2023_06_01
Reports
14
GlobalData

May 17, 2023 05:32 AM
XRTX
XORTX Therapeutics Inc (XRTX.CVE) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
Reports
29
Alliance Global Partners
Molloy, James Francis
May 08, 2023 05:05 AM
XRTX
Recent Accelerated Approval for XORLO shortens development by a full year, in our opinion
Reports
8
S&P Global Compustat

May 04, 2023 03:57 AM
XRTX
XORTX Therapeutics Inc 2023_05_04
Reports
14
Alliance Global Partners
Molloy, James Francis
Apr 24, 2023 09:40 AM
XRTX
Orphan Drug Designation a significant positive, Accelerated Approval designation expected next
Reports
5
Alliance Global Partners
Molloy, James Francis
Apr 10, 2023 09:35 AM
XRTX
Both Orphan Drug and Accelerated Approval Designation possible for XRTX in a couple of weeks
Reports
9


Ownership Summary

            Top Holders 
Holders by Type
Holder

Common Stock Equivalent Held

% of Total Shares Outstanding

Market Value (CAD in mm)

Position Date


Prevail Partners

977,318

5.43

0.8

Sep-20-2022


Davidoff Ph.D., Allen Warren

467,617

2.60

0.4

May-30-2023


Van Damme B.Com., CA, CPA, MBA, Paul Joseph

63,993

0.36

0.1

May-30-2023


Klassen B.A., B.A. (Hons), Ian Mcculloch

42,759

0.24

0.0

May-30-2023


Citadel Advisors LLC

28,109

0.16

0.0

Jun-30-2023


MacDonald Ph.D., David 

20,000

0.11

0.0

Apr-01-2022


Osaic Wealth, Inc. , Asset Management Arm

10,383

0.06

0.0

Jun-30-2023


Keshri C.A., CPA, Amar 

8,500

0.05

0.0

Nov-25-2022


Clearstead Advisors, LLC

2,500

0.01

0.0

Jun-30-2023


RBC Dominion Securities Inc., Asset Management Arm

121

0.00

0.0

Jun-30-2023



 



Top Buyers
Buyers
Common Stock Equivalent Held
Change
Citadel Advisors LLC
28,109
28,109
Davidoff Ph.D., Allen Warren
467,617
1,500
RBC Dominion Securities Inc., Asset Management Arm
121
33

Top Sellers
Sellers
Common Stock Equivalent Held
Change
Two Sigma Securities, LLC, Asset Management Arm
0
(24,038)
Susquehanna International Group, LLP, Asset Management Arm
0
(21,649)
Virtu Financial LLC, Asset Management Arm
0
(12,874)


S&P Global Ratings Credit Ratings
No S&P Global Ratings Credit Ratings data available. 


News Headlines
Date/Time
Headline
Source
Sep-12
XORTX Announces Participation at Upcoming Investor Conferences
ENP Newswire


Company Coverage
This company is not on any Coverage List.

Products
XRx-008 (Future), XRX-101 (Future), XRx-225 (Future)


Upcoming Events
Date/Time
Type
Oct-21-2023
Company Conference Presentations
Oct-21-2023
Conferences
Oct-25-2023
Special/Extraordinary Shareholders Meeting
* Future Events are subject to change.


Recent Major Filings

Key Filings
Filed On
Period Date
Company Name
Source
Form Type
Size
Oct-04-2023
Oct-04-2023
XORTX Therapeutics Inc. (TSXV:XRTX)
SEC
6-K
11 KB
Oct-04-2023
-
XORTX Therapeutics Inc. (TSXV:XRTX)
SEDAR
News Releases
324 KB
Oct-04-2023
Oct-25-2023
XORTX Therapeutics Inc. (TSXV:XRTX)
SEC
6-K
774 KB
Oct-03-2023
-
XORTX Therapeutics Inc. (TSXV:XRTX)
SEDAR
Management Proxy Materials
153 KB
Oct-03-2023
-
XORTX Therapeutics Inc. (TSXV:XRTX)
SEDAR
Management Proxy Materials
628 KB
Oct-03-2023
-
XORTX Therapeutics Inc. (TSXV:XRTX)
SEDAR
Management Proxy Materials
328 KB
Sep-28-2023
Sep-28-2023
XORTX Therapeutics Inc. (TSXV:XRTX)
SEC
6-K
14 KB
Sep-28-2023
-
XORTX Therapeutics Inc. (TSXV:XRTX)
SEDAR
News Releases
334 KB
Sep-12-2023
Sep-11-2023
XORTX Therapeutics Inc. (TSXV:XRTX)
SEC
6-K
10 KB
Sep-11-2023
-
XORTX Therapeutics Inc. (TSXV:XRTX)
SEDAR
News Releases
314 KB


Insider Trades
Holder Name
Trade Date Range
Security Type
Transacted Shares
Transaction Value Range (CAD)
Transaction Type
% Change
Source
Davidoff Ph.D., Allen Warren (Founder, CEO, President & Director)
Apr-13-2023
Class A Common Shares
1,500
1,450
Open Market Acquisition
0.32
Multiple
Davidoff Ph.D., Allen Warren (Founder, CEO, President & Director)
Mar-31-2023
Class A Common Shares
3,800
2,523
Open Market Acquisition
0.82
Multiple
-
Mar-31-2023
Class A Common Shares
1,800
1,183
Open Market Acquisition
-
Exchange Announcement
-
Mar-31-2023
Class A Common Shares
2,000
1,340
Open Market Acquisition
-
Exchange Announcement
Davidoff Ph.D., Allen Warren (Founder, CEO, President & Director)
Mar-27-2023
Class A Common Shares
3,800
2,492
Open Market Acquisition
0.83
Multiple
-
Mar-27-2023
Class A Common Shares
1,800
1,168
Open Market Acquisition
-
Exchange Announcement
-
Mar-27-2023
Class A Common Shares
2,000
1,324
Open Market Acquisition
-
Exchange Announcement
Davidoff Ph.D., Allen Warren (Founder, CEO, President & Director)
Mar-22-2023
Class A Common Shares
6,100
4,323
Open Market Acquisition
1.35
Multiple
-
Mar-22-2023
Class A Common Shares
2,500
1,776
Open Market Acquisition
-
Exchange Announcement
-
Mar-22-2023
Class A Common Shares
1,800
1,279
Open Market Acquisition
-
Exchange Announcement
-
Mar-22-2023
Class A Common Shares
1,800
1,269
Open Market Acquisition
-
Exchange Announcement
Davidoff Ph.D., Allen Warren (Founder, CEO, President & Director)
Feb-10-2023
Class A Common Shares
1,000
864
Open Market Acquisition
0.22
Multiple
Excluding Automatic Transactions
Key Board Members Details
Name
Title
Phone
Fax
Email
Giovinazzo, Anthony J.
Independent Chair of the Board
403 455 7727
-

Davidoff, Allen Warren
Founder, CEO, President & Director
1-403-607-2621
-
adavidoff@xortx.com
Klassen, Ian Mcculloch
Independent Director
(604) 899-0106
(604) 684-5793
ian@grandeportage.com
Van Damme, Paul Joseph
Independent Director
1.416.847.6905
-
pvandamme@wdcapital.ca
Bjornstad, Petter 
Member of Clinical Advisory Board
403 455 7727
-

Edelstein, Charles 
Member of the Advisory Board
403 455 7727
-

Farley, William J.
Independent Director
403 455 7727
-

Johnson, Richard J.
Member of Clinical Advisory Board
403 455 7727
-

Maese, Federico 
Member of Clinical Advisory Board
403 455 7727
-

Pratt, Raymond Dennis
Independent Director
403 455 7727
-

Rastogi, Anjay 
Member of the Clinical Advisory Board
403 455 7727
-

ter Keurs, Henk E. D. J.
Member of Scientific Advisory Board
403 455 7727
-

* denotes that the relationship is proprietary

Key Executives and Professionals Details
Name
Title
Phone
Fax
Email
Davidoff, Allen Warren
Founder, CEO, President & Director
1-403-607-2621
-
adavidoff@xortx.com
Fairbairn, James Neville
Interim Chief Financial Officer
403 455 7727
-

Rigopoulos, Nick 
Director of Communications
(617) 901-0785
-
nrigopoulos@xortx.com
Sans, David 
Director of Corporate Development
403 455 7727
-

Evans, Stacy 
Chief Business Officer
403 455 7727
-

Haworth, Stephen 
Chief Medical Officer
403 455 7727
-

MacDonald, David 
Consultant of Clinical Operations
403 455 7727
-

May, Charlotte 
Corporate Secretary
(416) 471-3366
-
cmay@xortx.com
* denotes that the relationship is proprietary

Historical Equity Pricing Data supplied by Interactive Data Pricing and Reference Data LLC 
S&P Credit Ratings and Research provided by 
No content (including ratings, credit-related analyses and data, valuations, model, software or other application or output therefrom) or any part thereof (Content) may be modified, reverse engineered, reproduced or distributed in any form by any means, or stored in a database or retrieval system, without the prior written permission of S&P Global Market Intelligence or its affiliates (collectively, S&P Global). The Content shall not be used for any unlawful or unauthorized purposes. S&P Global and any third-party providers, as well as their directors, officers, shareholders, employees or agents (collectively S&P Global Parties) do not guarantee the accuracy, completeness, timeliness or availability of the Content. S&P Global Parties are not responsible for any errors or omissions (negligent or otherwise), regardless of the cause, for the results obtained from the use of the Content, or for the security or maintenance of any data input by the user. The Content is provided on an "as is" basis. S&P GLOBAL PARTIES DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING, BUT NOT LIMITED TO, ANY WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR USE, FREEDOM FROM BUGS, SOFTWARE ERRORS OR DEFECTS, THAT THE CONTENT’S FUNCTIONING WILL BE UNINTERRUPTED OR THAT THE CONTENT WILL OPERATE WITH ANY SOFTWARE OR HARDWARE CONFIGURATION. In no event shall S&P Global Parties be liable to any party for any direct, indirect, incidental, exemplary, compensatory, punitive, special or consequential damages, costs, expenses, legal fees, or losses (including, without limitation, lost income or lost profits and opportunity costs or losses caused by negligence) in connection with any use of the Content even if advised of the possibility of such damages.

Credit-related and other analyses, including ratings, and statements in the Content are statements of opinion as of the date they are expressed and not statements of fact. S&P Global Market Intelligence’s opinions, analyses and rating acknowledgment decisions (described below) are not recommendations to purchase, hold, or sell any securities or to make any investment decisions, and do not address the suitability of any security. S&P Global Market Intelligence assumes no obligation to update the Content following publication in any form or format. The Content should not be relied on and is not a substitute for the skill, judgment and experience of the user, its management, employees, advisors and/or clients when making investment and other business decisions. S&P Global Market Intelligence does not act as a fiduciary or an investment advisor except where registered as such. While S&P Global Market Intelligence has obtained information from sources it believes to be reliable, S&P Global Market Intelligence does not perform an audit and undertakes no duty of due diligence or independent verification of any information it receives.

S&P Global keeps certain activities of its divisions separate from each other in order to preserve the independence and objectivity of their respective activities. As a result, certain divisions of S&P Global may have information that is not available to other S&P Global divisions. S&P Global has established policies and procedures to maintain the confidentiality of certain non-public information received in connection with each analytical process.

S&P Global Ratings does not contribute to or participate in the creation of credit scores generated by S&P Global Market Intelligence. Lowercase nomenclature is used to differentiate S&P Global Market Intelligence PD credit model scores from the credit ratings issued by S&P Global Ratings.

S&P Global may receive compensation for its ratings and certain analyses, normally from issuers or underwriters of securities or from obligors. S&P Global reserves the right to disseminate its opinions and analyses. S&P Global's public ratings and analyses are made available on its Web sites, www.standardandpoors.com (free of charge), and www.capitaliq.com (subscription), and may be distributed through other means, including via S&P Global publications and third-party redistributors. Additional information about our ratings fees is available at www.standardandpoors.com/usratingsfees.
Regulatory News Service data provided by 

**Intraday Quotes are delayed by at least 20 minutes.
